Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts

Anti-Cancer Drugs

Volumn 17, Issue 5, 2006, Pages 559-563

  Massart, Catherine ^a   Denais, Annick ^b   Gibassier, Jaqueline ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

All trans retinoic acid; Nude mice; Sodium butyrate; Thyroid cancer

Indexed keywords

ALKALINE PHOSPHATASE; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 33748168323     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200606000-00010     Document Type: Article

References (36)

1. Robbins J, Merino MJ, Boice JD, Ron E, Ain KB, Alexander HR, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991; 115:133-147.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
3. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary carcinoma. J Clin Endocrinol Metab 1996; 81:333-339.
4. Degroot LJ. Long-term impact of initial and surgical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:499-500.
5. Bergé-Lefranc JL, Cartouzou G, De Micco C, Fragu P, Lissitzky S. Quantification of thyroglobulin messenger RNA by in situ hybridization in differentiated thyroid cancers. Difference between well-differentiated and moderately differentiated histologic types. Cancer 1985; 56:345-350.
6. Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E, Piampani P, et al. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab 2005; 90:2403-2411.
7. Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol 1987; 10:187-194.
8. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers. Cancer 1985; 55:2062-2071.
9. Jossart GH, Clark OH. Well-differentiated thyroid cancer. Curr Probl Surg 1994; 31:933-1012.
10. Schmutzler C, Brtko J, Bienert K, Köhrle J. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 1996; 104:16-19.
11. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997; 240:832-838.
12. Schreck R, Schnieders F, Schmuzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5′-deodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994; 79:791-798.
13. Kitazano M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:834-840.
14. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:3430-3435.
15. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodine uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004; 145:2865-2875.
16. Simon D, Köhrle J, Reiners C, Boerner AR, Schmuzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22:569-574.
17. Grüning T, Tiepolt C, Zöphel K, Bredow J, Kropp J, Franke WG. Retinoic acid for differentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003; 148:395-402.
18. Cummings JH. Short chain fatty acids in the human colon. Gut 1981; 22:763-779.
19. Candido EPM, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978; 14:105-113.
20. Massart C, Poirier C, Fergelot P, Fardel O, Gibassier J. Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells. Anticancer Drugs 2005; 16:255-261.
21. - symporter gene methylation status. J Clin Endocrinol Metab 1999; 84:2449-2457.
22. Greenberg VL, Williams JM, Boghaert E, Mendenhall M, Ain KB, Zimmer SG. Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid 2001; 11:21-28.
23. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 2001; 11:315-325.
24. Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391:811-814.
25. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61:1477-1485.
26. Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, et al. In vivo imaging of retinoic receptor beta2 transcriptional activation by the histone deacetylase inhibitors MS-275 in retinoid-resistant prostate cancer cells. Prostate 2005; 64:20-28.
27. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RAR beta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002; 62:2455-2461.
28. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005; 11:3535-3542.
29. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, et al. Retinoic acid and the histone deacetylase inhibitor trichostatin A inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005; 11:3558-3566.
30. Massart C, Gibassier J, Raoul ML, Denais A, Maugendre D, Darcel F, et al. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid xenograft. Anticancer Drugs 1996; 7:321-330.
31. Schmutzler C, Hoang-Vu C, Rüger B, Köhrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol 2004; 150:547-556.
32. Sidell N, Chang B, Yamashiro JM, Wada RK. Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res 1998; 239:169-174.
33. Eigelberger MS, Wong MG, Duh QY, Clark OH. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer. Surgery 2001; 130:931-935.
34. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004; 89:272-280.
35. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000; 85:2889-2896.
36. Yeung SCJ, Xu G, Pan J, Christgen M, Bamiagis A. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000; 60:650-656.